DWM
ALNY icon

Dynasty Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Dynasty Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
747
-487
-39% -$147K ﹤0.01% 347
2026
Q1 		$408K Buy
1,234
+546
+79% +$186K ﹤0.01% 256
2025
Q4 		$274K Buy
688
+20
+3% +$8.85K ﹤0.01% 300
2025
Q3 		$305K Buy
+668
New +$272K ﹤0.01% 261

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dynasty Wealth Management's ALNY Position: Q2 2026 in Review

Dynasty Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 39% in Q2 2026, selling an estimated $147K and leaving 747 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #347.

Dynasty Wealth Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $408K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Dynasty Wealth Management held 747 shares of Alnylam Pharmaceuticals worth $225K as of Q2 2026.
  • Dynasty Wealth Management sold 487 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $147K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Dynasty Wealth Management's portfolio in Q2 2026, its #347 holding.
  • Dynasty Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Dynasty Wealth Management's Alnylam Pharmaceuticals position peaked at $408K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Dynasty Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.